Q: Is 360 High-Risk Vulnerability Immunization Tool V2.0 a good alternative to Fortra VM?

360 High-Risk Vulnerability Immunization Tool V2.0 and Fortra VM serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools. Review the feature comparison above to determine which fits your requirements.

Question 1

What is the difference between 360 High-Risk Vulnerability Immunization Tool V2.0 vs Fortra VM?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0**: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). headquartered in China. Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

**Fortra VM**: Risk-based vulnerability management platform for scanning and prioritization. built by Fortra. headquartered in United States. Core capabilities include Vulnerability scanning and identification, Risk-based vulnerability prioritization, Threat ranking based on real-world exploitation vectors..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

Question 2

What features do 360 High-Risk Vulnerability Immunization Tool V2.0 vs Fortra VM offer?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0** differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. **Fortra VM** differentiates with Vulnerability scanning and identification, Risk-based vulnerability prioritization, Threat ranking based on real-world exploitation vectors.

Question 3

Who makes 360 High-Risk Vulnerability Immunization Tool V2.0 vs Fortra VM?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0** is developed by 360 Security Group (Qihoo 360). **Fortra VM** is developed by Fortra. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.